# HCW Biologics (HCWB) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/HCWB
## Company Profile
- Ticker: HCWB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Immunology
## Stock Data
- Close: 3.17 USD
- Market cap: 12818458.5 USD
- Last updated: 2026-08-11
## Business Overview
### Fusion Immunotherapy Company
HCW Biologics develops fusion immunotherapies for autoimmune disease, cancer, and age-related dysplasia. Its platform is based on the role of chronic inflammation across multiple disease areas.
### HCW9302 Autoimmune Program
HCW9302 is an injectable, first-in-kind IL-2 fusion protein complex being developed for alopecia areata. It is designed to activate and expand regulatory T cells, thereby suppressing autoreactive immune cells that attack hair follicles.
### Fusion Cytokine Platform
HCW’s platform combines immune-active proteins into engineered fusion complexes intended to shape specific immune-cell populations. The same design capabilities support programs in immune tolerance, oncology, and cell-therapy manufacturing.
### Platform and Licensing Strategy
HCW combines internal development with business development and has licensed selected proprietary molecules to external partners. Data for HCW9206 as a reagent also suggest potential use in CAR T-cell manufacturing.
## Why The Stock Is Moving

As of Aug 11, 2026, HCWB closed down 3.06% at $3.17. No new same-company headline was identified in the current news window.

## Future Catalysts

- Preliminary clinical data from the first two dose levels of the Phase 1 HCW9302 study in alopecia areata were expected in the first half of 2026.
- A complete Phase 1 human data readout for HCW9302 is expected in the fourth quarter of 2026.

## Recent News
- 2026-07-29 13:06 EST — [HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering](https://biopharmsignal.com/news/HCWB/hcw-biologics-inc-announces-pricing-of-1-6-million-private-placement-offering-ea86202c) — Source: HCW Biologics
- 2026-07-23 12:00 EST — [HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027](https://biopharmsignal.com/news/HCWB/hcw-biologics-reaches-milestones-for-its-proprietary-tetravalent-second-generati-fd18e4a2) — Source: HCW Biologics
- 2026-06-30 12:25 EST — [HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter](https://biopharmsignal.com/news/HCWB/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-lett-e27131c5) — Source: HCW Biologics
- 2026-06-26 12:55 EST — [HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026](https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-1-for-6-reverse-stock-split-effective-on-june-30-2026-31a4d4f1) — Source: HCW Biologics
- 2026-06-16 11:00 EST — [HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata](https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-positive-results-for-preliminary-human-data-readout-for--d173c93d) — Source: HCW Biologics